The anti‐HER2 antibody, trastuzumab, has proven to be an effective targeted therapy, showing significant efficacy in the treatment of HER2‐positive breast cancer,46 gastric cancer,47 and gastroesophageal (GE) junction adenocarcinoma.48 The gene discussed is ERBB2; the disease is breast carcinoma.